PubMed Health⌕ Search

Biomedical subjects

Christian Butter

Publications and source records attributed to Christian Butter.

10 recordsLinked to original sources
PubMed2006

Time course of left ventricular volumes in severe congestive heart failure patients treated by optimized AV sequential left ventricular pacing alone--a 3-dimensional echocardiographic study.

BACKGROUND: This study evaluates the acute and chronic resynchronizing effects of AV sequential left ventricular (LV) pacing on LV function in patients with impaired cardiac function and conduction disorders by 3-dimensional transesophageal echocardiography. METHODS AND RESULTS: Twenty-nine patients with congestive heart failure, with LV ejection fraction (LVEF) < or = 30%, QRS duration > or = 120 milliseconds, and New York Heart Association Class II to IV, were implanted with a cardiac resynchronization device using an LV lead only, according to the invasively determined hemodynamic optimal pacing site and AV delay. Patients underwent 3-dimensional transesophageal echocardiography before randomization to treatment (baseline) and at 12-month follow-up (resynchronization--12 months). Three-dimensional volumes were acquired on resynchronization and during intermittent switch-off at intrinsic depolarization. The values of stroke volume were 43.2 +/- 13.3 (intrinsic-baseline), 51.7 +/- 17.4 (intrinsic--12 months), 57.2 +/- 15.6 (resynchronization-baseline), and 64.6 +/- 18.9 (resynchronization--12 months). Analysis of variance demonstrated a significant effect of resynchronization at different periods (P < .001) and a significant time effect (P < .05) for stroke volume. Similar results were observed with ejection fraction (LVEF). No effect was observed with LV end-diastolic volume, whereas a therapy effect with no time effect was observed with LV end-systolic volume. CONCLUSIONS: A significant acute increase of LV stroke volume and LVEF was found by resynchronization by LV pacing alone. A continuous improvement of LV stroke volume and LVEF occurred with time of follow-up (reverse remodeling). The initial therapeutic effect persisted during 12-month follow-up independently of time of follow-up and QRS width. No significant decrease of LV end-diastolic size during chronic resynchronization was detected in contrast to previous studies with resynchronization by biventricular pacing.

Cardiac Pacing, Artificial↗
PubMed2006

Intravascular misplacement of an extravascular closure system: StarClose.

Closure devices for closing femoral arteries following catheterization procedures are routinely used. They reduce time of immobilization and decrease complications such as bleeding and aneurysm formation. We report of a new vascular closure device (StarClose, marketed by Abbott) that was misplaced in the femoral artery with subsequent vascular stenosis and need for surgical removal and plastic reconstruction.

Angiography↗
PubMed2005

Electrical signals applied during the absolute refractory period: an investigational treatment for advanced heart failure in patients with normal QRS duration.

Cardiac resynchronization therapy has been shown to be an effective treatment for patients with systolic ventricular dysfunction, prolonged (>120 ms) QRS duration, and New York Heart Association (NYHA) functional class III or IV symptoms despite optimal medical therapy. However, studies show that a majority of heart failure patients have QRS duration <120 ms. We have been investigating the potential utility of cardiac contractility modulating (CCM) signals as a treatment option for such patients. Cardiac contractility modulating signals are non-excitatory signals applied during the absolute refractory period using a pacemaker-like device that connects to the heart with pacemaker leads. Acute studies carried out in animals and humans with heart failure suggest that CCM signals can enhance the strength of left ventricular contraction. Results of initial long-term studies designed mainly to demonstrate feasibility and provide preliminary indication of safety in patients with medically refractory NYHA functional class III heart failure are summarized. The results of these preclinical and clinical studies formed the basis for proceeding with two prospective, randomized clinical studies currently underway to definitively test the safety and efficacy of this treatment.

Animals↗
PubMed2004

Panic disorders and agoraphobia: side effects of treatment with an implantable cardioverter/defibrillator.

BACKGROUND: Implantable cardioverter/defibrillator (ICD) treatment has reduced the mortality of patients with a high risk of sudden cardiac death. However, ICD discharges may cause anxiety with respect to new discharges and lead to preventive, for example, phobic, behavior. This study evaluated the frequency of panic disorders and agoraphobia in patients with ICD and assessed the risk factors in their development. HYPOTHESIS: Treatment with ICD represents a risk factor in the development of anxiety disorders. METHODS: Ninety patients with ICD were examined using a standardized lifetime Diagnostic Interview of Psychiatric Syndromes (DIPS). This interview makes it possible to estimate the incidence of panic disorders and agoraphobia. The impact of the severity of the underlying cardiac disease, the number of ICD discharges, and the subjective appraisal of the shock experience on the development of panic disorders and agoraphobia was assessed. RESULTS: Fifteen patients (16.7%) developed anxiety disorders after ICD implantation. The incidence was 21% in patients with and 6.9% in patients without ICD discharge. In patients with two or more ICD discharges annually, the incidence of panic disorders and agoraphobia was higher than that in patients with a single ICD discharge annually (62 vs. 10%, p<0.01). The intensity of self-observation of their body was significantly related to the development of anxiety disorders (p<0.001). CONCLUSION: Panic disorders and agoraphobia are frequent side effects of ICD treatment. Risk factors in the development of these disorders are two or more ICD discharges annually and a negative cognitive appraisal of ICD discharges. Therapeutic efforts should aim at reducing the number of ICD discharges and provide early psychological treatment.

Adaptation, Psychological↗
PubMed2004

Cardiac resynchronization therapy optimization by finger plethysmography.

OBJECTIVES: We tested a simple noninvasive method for cardiac resynchronization therapy (CRT) optimization using standard finger photoplethysmography (FPPG). BACKGROUND: CRT can increase left ventricular cardiac output in patients with heart failure and ventricular conduction delay. Optimal therapy delivery depends on an appropriate AV delay. Multiple invasive and noninvasive methods have been attempted to identify patients and the best AV delay for CRT, but all suffer from a combination of high patient risk, cost, complexity, and low reproducibility. METHODS: FPPG and invasive aortic pressure data were simultaneously collected from 57 heart failure patients during intrinsic rhythm alternating with very brief periods of pacing at 4 to 5 AV delays. After correcting data for artifacts, the median percentage responses for each AV delay were classified as positive, negative, or neutral compared to baseline (Wilcoxon rank test). RESULTS: FPPG correctly identified positive aortic pulse pressure responses with 71% sensitivity (95% CI: 60-80%) and 90% specificity (95% CI: 84-94%) and negative aortic pulse pressure responses with 57% sensitivity (95% CI: 44-69%) and 96% specificity (95% CI: 91-98%). The magnitude of FPPG changes were strongly correlated with positive aortic pulse pressure changes (R(2) = 0.73, P < .0001) but less well correlated with negative aortic pulse pressure changes (R(2) = 0.43, P < .0001). FPPG selected 78% of the patients having positive aortic pulse pressure changes to CRT and identified the AV delay giving maximum aortic pulse pressure change in all selected patients. CONCLUSIONS: FPPG can provide a simple noninvasive method for identifying significant changes in aortic pulse pressure with high specificity, including identifying patients in whom aortic pulse pressure increases with CRT and the AV delay giving the maximum aortic pulse pressure.

Aorta↗
PubMed2003

Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay.

OBJECTIVES: We assessed the clinical efficacy of single-site left ventricular (LV) pacing and determined the impact of baseline conduction delay severity on the magnitude of benefit. BACKGROUND: Multisite biventricular pacing can improve heart failure (HF) symptoms in patients with an intraventricular conduction delay by resynchronizing abnormal ventricular contractions and improving LV systolic function. METHODS: Eighty-six patients with at least New York Heart Association functional class II HF, chronic LV systolic dysfunction, normal sinus rhythm, and a QRS interval over 120 ms were implanted for atrial-synchronized LV pacing. The single-blinded, randomized, controlled, crossover study stratified patients 1:1 by the baseline QRS interval into long (QRS >150 ms) and short (QRS 120 to 150 ms) groups, which were compared during a three-month period of active (univentricular) pacing and a three-month period of inactive (ventricular inhibited) pacing. The primary end point was peak oxygen consumption (VO(2)) followed by anaerobic threshold, distance walked in 6 min, and quality-of-life questionnaire score. PATIENTS: Twelve patients were withdrawn before randomization and 17 could not complete both study periods. The short QRS group did not improve in any end point with active pacing. For the long QRS group, peak VO(2) increased 2.46 ml/min/kg (p < 0.001), the anaerobic threshold increased 1.55 ml/min/kg (p < 0.001), the distance walked in 6 min increased 47 m (p = 0.024), and the quality-of-life score improved 8.1 points (p = 0.004). CONCLUSIONS: Left ventricular pacing significantly improves exercise tolerance and quality of life in patients with chronic HF, LV systolic dysfunction, and a QRS interval over 150 ms.

Adolescent↗
PubMed2003

Comparative prospective randomized efficacy testing of different guiding catheters for coronary sinus cannulation in heart failure patients.

INTRODUCTION: The efficacy of different shapes of guiding catheters for coronary sinus (CS) cannulation was evaluated at implant of a cardiac resynchronization therapy device that required transvenous placement of a pacing lead in a coronary vein on the left ventricle. METHODS AND RESULTS: Comparative testing of 5 different guiding catheter shapes was attempted in 29 consecutive patients. Four newer guiding catheters were tested in a prospective randomized manner with a reference standard catheter always tested in the last place. All of the new catheters included a distal shape that consisted of a single curve or a compound set of curves at the catheter tip, followed by a catheter shaft design which fell into one of two classes: (1). straight shaft catheters and (2). curved shaft catheters. The curved shaft class of catheters, two new and one standard, achieved higher (16/23 (70%), 17/23 (74%) and 17/22 (77%)) CS cannulation success rates than the straight shaft class catheters ((13/23 (56%) and 12/23 (52%)). The pairing of two catheters, one from each class in a single patient, or both from the curved shaft class resulted in a combined CS cannulation success rate of up to 96%. Two of the catheters were more effective from a left hand insertion than from a right hand insertion site. CONCLUSIONS: The ability to switch between guiding catheters with different shapes and compound curves can improve the CS cannulation success rate. The selection of guiding catheters should be influenced by the intended use of the catheter either from the left or from the right hand side.

Cardiac Catheterization↗
PubMed2002

Human experience with transvenous biventricular defibrillation using an electrode in a left ventricular vein.

This study investigated the safety and feasibility of transvenous biventricular defibrillation in ICD patients. Some patients may have high DFTs due to weak shock field intensity on the LV. Animal studies showed a LV shocking electrode dramatically lowered DFTs. This approach might benefit heart failure patients already receiving a LV lead or conventional ICD patients with high DFTs. A modified guidewire was used as a temporary left venous access defibrillation electrode (LVA lead). In 24 patients receiving an ICD, the LVA lead was advanced through a guide catheter in the coronary sinus (CS) and into a randomized LV vein (anterior or posterior) using a venogram for guidance. Paired DFT testing compared a standard right ventricular defibrillation system to a biventricular defibrillation system. There were no complications or adverse events. As randomized, LVA lead insertion success was 87% and 71% for anterior and posterior veins, respectively, and 100% after crossover. Total insertion process time included venogram time (32.5 +/- 26.9 minutes, range 5-115, mode 15 minutes) and LVA lead insertion time (15 +/- 14 minutes, range 1-51, mode 7 minutes). An apical LVA lead position was achieved in 11 (45%) of 24 patients and 7 (64 %) of these 11 displayed a DFT reduction; however, mean DFTs were not statistically different. Transvenous biventricular defibrillation is feasible and was safe under the conditions tested. Additional clinical studies are justified to determine if optimized LV lead designs, lead placement, and shock configurations can yield the same large DFT reductions as observed in animals.

Aged↗